Financial Contrast: OncoSec Medical (ONCS) and Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (NASDAQ: IONS) and OncoSec Medical (NASDAQ:ONCS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ionis Pharmaceuticals and OncoSec Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals 2 5 6 0 2.31
OncoSec Medical 0 0 5 0 3.00

Ionis Pharmaceuticals currently has a consensus price target of $50.92, suggesting a potential upside of 8.91%. OncoSec Medical has a consensus price target of $5.00, suggesting a potential upside of 204.88%. Given OncoSec Medical’s stronger consensus rating and higher probable upside, analysts plainly believe OncoSec Medical is more favorable than Ionis Pharmaceuticals.

Insider and Institutional Ownership

91.4% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.3% of OncoSec Medical shares are owned by institutional investors. 2.1% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of OncoSec Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Ionis Pharmaceuticals has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, OncoSec Medical has a beta of 3.34, indicating that its share price is 234% more volatile than the S&P 500.

Profitability

This table compares Ionis Pharmaceuticals and OncoSec Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals 3.46% 7.50% 1.58%
OncoSec Medical N/A -144.61% -110.75%

Earnings & Valuation

This table compares Ionis Pharmaceuticals and OncoSec Medical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals $346.62 million 16.83 -$86.55 million $0.15 311.69
OncoSec Medical N/A N/A -$21.44 million ($1.06) -1.55

OncoSec Medical has lower revenue, but higher earnings than Ionis Pharmaceuticals. OncoSec Medical is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Ionis Pharmaceuticals beats OncoSec Medical on 8 of the 13 factors compared between the two stocks.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply